Skip to content

A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users

A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02192931
Enrollment
65
Registered
2014-07-17
Start date
2014-09-30
Completion date
2023-01-31
Last updated
2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Drug Addiction, Dual Diagnosis

Brief summary

Methamphetamine (MA) addiction is a public health concern that causes substantial harm to individual users, and imposes an economic burden in the U.S. totaling up to $48.3 billion annually. This study proposes to address a critical aspect of this problem: the lack of any proven, FDA-approved pharmacological treatments for MA users. The proposal combines an intervention designed to improve energy metabolism in the brain, and a neuroimaging technique capable of measuring the neurochemicals that represent cerebral bioenergetic function. The study will replicate and extend a key neuroimaging finding from the investigators recent MA studies: that MA users have decreased phosphocreatine (PCr) levels in the brain, compared to healthy volunteers. Phosphocreatine is the substrate reservoir for the creatine kinase reaction, which reversibly converts PCr into adenosine triphosphate (ATP), the brain's major energy supply, and creatine. Neuronal energy demands are met through a shift in reaction equilibrium, which is designed to maintain the concentration of ATP constant. Research results from the investigators recent study also showed that female MA users have lower brain PCr levels compared to male users. These findings join the converging lines of evidence that MA use is associated with mitochondrial dysfunction, i.e. deficient energy metabolism, in the brain. Frequently, MA users also experience depression, as well as cognitive deficits. Interestingly, both of these entities are also linked to mitochondrial dysfunction in the brain. The long-term goal of this research program is to define the alterations in brain chemistry that underlie MA use disorders, and to utilize translational magnetic resonance spectroscopy (MRS) neuroimaging to identify rational brain-based treatment targets. Once a hypothesis-driven intervention is identified, MRS can then be further employed in treatment studies, to verify that target engagement is achieved. The specific aims of this proposal are an example of this stepwise scientific process: the nutritional supplement creatine will be tested in a randomized, placebo-controlled study of women with MA use disorders, to investigate creatine's effect on cerebral PCr levels, depressive symptoms, and MA usage.

Interventions

DRUGCreatine monohydrate

Sponsors

Perry Renshaw
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Female gender, ages 18-55 inclusive * Current primary diagnosis of MA dependence or abuse, with MA preferred drug of abuse * Current diagnosis of Major Depressive Disorder * Current HAMD score \> 15 * Clinical Global Impressions Severity depression score \> 4 * If currently taking a psychotropic medication for depressed mood, regimen must be stable for \> 4 weeks before randomization

Exclusion criteria

* Persons unable to provide adequate consent * Persons who are at clinically significant suicidal or homicidal risk * Primary substance-related diagnosis other than MA dependence or abuse * Comorbid substance dependence diagnosis, other than nicotine (substance abuse diagnoses are not excluded) * Positive pregnancy test * Positive test for the antibody to the Human Immunodeficiency Virus (HIV) * History of renal disease

Design outcomes

Primary

MeasureTime frameDescription
Hamilton Depression Rating Scale (HAMD) Scores8-weeksChange in Hamilton Depression Rating Scale (HAMD) scores will be evaluated over the course of the 8-week treatment period. The HAMD provides an indication of depression and over time provides a valuable guide to progress. Total score ranges from 0 to 54. 0 means no depression and 24 and above means severe depression.

Secondary

MeasureTime frameDescription
Beck Anxiety Inventory (BAI) Scores8-weeksChange in Beck Anxiety Inventory (BAI) scores will be evaluated over the course of the 8-week treatment period. The BAI aims to assess the severity of anxiety symptoms, helping clinicians and researchers understand the level of anxiety an individual is experiencing. 0 means minimal anxiety and 30-63 means severe anxiety. The scale ranges from 0 to 63. Total score is reported.

Other

MeasureTime frameDescription
BL Neurochemistry Measured by Magnetic Resonance SpectroscopyBaselineNeurochemistry, such as phosphocreatine (PCr), will be measured pre- and post-creatine/placebo treatment.
Neurochemistry Measured by Magnetic Resonance Spectroscopy TX8-weeksNeurochemistry, such as phosphocreatine (PCr), will be measured pre- and post-creatine/placebo treatment.

Countries

United States

Participant flow

Recruitment details

We complied with safety measures meant to minimize the risk of exposure to COVID-19. Participant recruitment were facilitated by advertisements in newspapers, on the radio, by hanging recruitment materials, on the Internet, and by sending letters to social workers and staff at treatment centers. To increase the study's enrollment of healthy controls, we distributed materials specifically aimed at healthy controls.

Participants by arm

ArmCount
Creatine Monohydrate
5 grams of daily creatine monohydrate for 8 weeks Creatine monohydrate
21
Placebo
5 g of placebo for 8 weeks Creatine monohydrate
20
Healthy Control
Measured at baseline.
24
Total65

Baseline characteristics

CharacteristicCreatine MonohydratePlaceboHealthy ControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
21 Participants20 Participants24 Participants65 Participants
Age, Continuous37.4 years
STANDARD_DEVIATION 7.1
34.2 years
STANDARD_DEVIATION 10
30.8 years
STANDARD_DEVIATION 10.5
33.8 years
STANDARD_DEVIATION 9.6
Race/Ethnicity, Customized
Race
Asian
0 Participants0 Participants2 Participants2 Participants
Race/Ethnicity, Customized
Race
Caucasian
18 Participants17 Participants18 Participants53 Participants
Race/Ethnicity, Customized
Race
Hispanic/Latino
3 Participants2 Participants4 Participants9 Participants
Race/Ethnicity, Customized
Race
More than one race
0 Participants0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Race
Native American
0 Participants1 Participants0 Participants1 Participants
Region of Enrollment
United States
21 participants20 participants24 participants65 participants
Sex: Female, Male
Female
21 Participants20 Participants24 Participants65 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 210 / 200 / 24
other
Total, other adverse events
3 / 217 / 200 / 24
serious
Total, serious adverse events
0 / 210 / 200 / 24

Outcome results

Primary

Hamilton Depression Rating Scale (HAMD) Scores

Change in Hamilton Depression Rating Scale (HAMD) scores will be evaluated over the course of the 8-week treatment period. The HAMD provides an indication of depression and over time provides a valuable guide to progress. Total score ranges from 0 to 54. 0 means no depression and 24 and above means severe depression.

Time frame: 8-weeks

Population: Due to participant attrition, data analyzed in one or more rows differed from the overall number analyzed.

ArmMeasureGroupValue (MEAN)Dispersion
Creatine MonohydrateHamilton Depression Rating Scale (HAMD) ScoresBaseline Scan16.24 score on a scaleStandard Deviation 3.91
Creatine MonohydrateHamilton Depression Rating Scale (HAMD) ScoresScreening16.76 score on a scaleStandard Deviation 3.33
Creatine MonohydrateHamilton Depression Rating Scale (HAMD) ScoresWeek 8 Final Scan9.33 score on a scaleStandard Deviation 3.58
PlaceboHamilton Depression Rating Scale (HAMD) ScoresBaseline Scan14.90 score on a scaleStandard Deviation 4.1
PlaceboHamilton Depression Rating Scale (HAMD) ScoresScreening17.65 score on a scaleStandard Deviation 4.66
PlaceboHamilton Depression Rating Scale (HAMD) ScoresWeek 8 Final Scan8.18 score on a scaleStandard Deviation 7.26
Healthy ControlHamilton Depression Rating Scale (HAMD) ScoresScreening1.67 score on a scaleStandard Deviation 1.9
Healthy ControlHamilton Depression Rating Scale (HAMD) ScoresWeek 8 Final Scan1.88 score on a scaleStandard Deviation 2.58
Healthy ControlHamilton Depression Rating Scale (HAMD) ScoresBaseline Scan1.58 score on a scaleStandard Deviation 2.21
Secondary

Beck Anxiety Inventory (BAI) Scores

Change in Beck Anxiety Inventory (BAI) scores will be evaluated over the course of the 8-week treatment period. The BAI aims to assess the severity of anxiety symptoms, helping clinicians and researchers understand the level of anxiety an individual is experiencing. 0 means minimal anxiety and 30-63 means severe anxiety. The scale ranges from 0 to 63. Total score is reported.

Time frame: 8-weeks

Population: Due to participant attrition, data analyzed on one or more rows differ from the overall number analyzed.

ArmMeasureGroupValue (MEAN)Dispersion
Creatine MonohydrateBeck Anxiety Inventory (BAI) ScoresWeek 8 Final Scan6.00 score on a scaleStandard Deviation 5.2
Creatine MonohydrateBeck Anxiety Inventory (BAI) ScoresScreening22.76 score on a scaleStandard Deviation 12.7
Creatine MonohydrateBeck Anxiety Inventory (BAI) ScoresBaseline20.81 score on a scaleStandard Deviation 12
PlaceboBeck Anxiety Inventory (BAI) ScoresBaseline24.60 score on a scaleStandard Deviation 13.56
PlaceboBeck Anxiety Inventory (BAI) ScoresWeek 8 Final Scan12.82 score on a scaleStandard Deviation 18
PlaceboBeck Anxiety Inventory (BAI) ScoresScreening29.25 score on a scaleStandard Deviation 12.08
Healthy ControlBeck Anxiety Inventory (BAI) ScoresScreening3.63 score on a scaleStandard Deviation 4.67
Healthy ControlBeck Anxiety Inventory (BAI) ScoresWeek 8 Final Scan3.64 score on a scaleStandard Deviation 4.23
Healthy ControlBeck Anxiety Inventory (BAI) ScoresBaseline4.13 score on a scaleStandard Deviation 4.67
Other Pre-specified

BL Neurochemistry Measured by Magnetic Resonance Spectroscopy

Neurochemistry, such as phosphocreatine (PCr), will be measured pre- and post-creatine/placebo treatment.

Time frame: Baseline

Population: Phosphocreatine (Baseline comparison between creatine and placebo)

ArmMeasureValue (MEAN)
Creatine MonohydrateBL Neurochemistry Measured by Magnetic Resonance Spectroscopy0.268 ratio
PlaceboBL Neurochemistry Measured by Magnetic Resonance Spectroscopy0.268 ratio
Other Pre-specified

Neurochemistry Measured by Magnetic Resonance Spectroscopy TX

Neurochemistry, such as phosphocreatine (PCr), will be measured pre- and post-creatine/placebo treatment.

Time frame: 8-weeks

Population: Phosphocreatine (Treatment comparison between creatine and placebo)

ArmMeasureValue (MEAN)
Creatine MonohydrateNeurochemistry Measured by Magnetic Resonance Spectroscopy TX0.291 ratio
PlaceboNeurochemistry Measured by Magnetic Resonance Spectroscopy TX0.269 ratio

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026